D. Marazziti - Vol. 10, December 2004, Issue 4
Testo Bibliografia Summary Indice
Serotonina e psicopatologia
Serotonin and psychopathology
1 Young S, Smith S, Pihl R, Ervin F. Tryptophan depletion causes a rapid lowering of mood in normal subjects. Psycopharmacology 1985;87:173-7.
2 Delgado P, Charney D, Price L, Aghajanian G, Andes H, Heninger G. Serotonine function and the mechanism of antidepressant action. Reversal of anti depressant induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-8.
3 Meltzer H. Role of serotonine in depression. Ann NY Acad Sci 1990;487:486-500.
4 Maes M, Meltzer H. The serotonin hypotesis of major depression. In: Bloom F, Kupfer D, eds. Psycopharmacology: the Fourth generation of preogress. New York: Raven Press 1995, pp. 933-944.
5 Pine DS, Coplan JD, Wasserman GA, Miller LS, Fried JE, Davies M, et al. Neuroendocrine response to fenfluramine challenge in boys: associations with aggressive behaviour and adverse rearing. Arch Gen Psychiatry 1997;44:839-46.
6 Kaufman J, Birmaher B, Perel J, Dahl RE, Stull S, Brent D, et al. Serotoninergic function in depressed abused children: clinical and familiar correlates. Biol Psychiatry 1998;44:973-81.
7 Cadoret RJ, Leve LD, Devor E. Genetics of aggressive and violent behaviour. Psychiatr Clin North Am 1997;20:301-22.
8 Roy A, Nielsen D, Rylander G, Sarchiapone M, Segal N. Genetics of suicide in depression. J Clin Psychiatry 1999;60(Suppl 2):12-7.
9 McGue M, Bacon S, Lykken DT. Personality stability and change in early adulthood: a behavioural genetic analysis. Dev Psychol 1993;29:96-100.
10 Benjamin J, Gershon S. Genetic discoveries in human behavior: small effect genes loom large. Biol Psychiatry 1996;40:3B.
11 Mendels J, Frazer A, Fitzgerald RG, Ramsey TA, Stokes JW. Biogenic amine metabolites in cerebrospinal fluid of depressed and manic patients. Science 1972;175:1380-2.
12 Asberg M, Bertilsson L, Martensson B, Scalia-Tomba GP, Thoren P, Traskman-Bendz L. CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 1984;69:201-19.
13 Martensson B, Nyberg S, Toresson G, Brodin E, Bertilsson L. Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand 1989;79:586-96.
14 Brown SL, Botsis AJ, van Praag HM. Suicide: CSF and neuroendocrine challenge studies. Int Rev Psychiatry 1992;4:141-8.
15 Mann JJ. Role of the serotoninergic system in the pathogenesis of major depression and suicidal behavior. Neuropsychopharmacology. 1999; 21(Suppl 2):99S-105S.
16 Smith KA, Cowen PJ. Serotonin and depression. In: Honig A, van Prag HM, eds. Depression: Neurobiological, Psychopatological and Therapeutic Advantages. Chichester: Wiley 1997, pp. 129-146.
17 Stahl SM, Ciaranello RD, Berger PA. Platelet serotonin in schizophrenia and depression. Adv Biochem Psychopharmacol 1982;34:183-98.
18 Tuomisto J, Tukiainen E. Depressed uptake of 5-hydroxytryptamine in blood platelets from depressed patients. Nature 1976;262:596-8.
19 Meltzer HY, Perline R, Tricou BJ, Lowy M, Robertson A. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis, and depressive symptoms. Arch Gen Psychiatry 1984;41:379-87.
20 Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK. Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter". Arch Gen Psychiatry 1981;38:1315-7.
21 Raisman R, Sechter D, Briley MS, Zarifian E, Langer SZ. High-affinity 3H-imipramine binding in platelets from untreated and treated depressed patients compared to healthy volunteers. Psychopharmacology 1981;75:368-71.
22 Roy A, Everett D, Pickar D, Paul SM. Platelet tritiated imipramine binding and serotonin uptake in depressed patients and controls. Relationship to plasma cortisol levels before and after dexamethasone administration. Arch Gen Psychiatry 1987;44:320-7.
23 Innis RB, Charney DS, Heninger GR. Differential 3H-imipramine platelet binding in patients with panic disorder and depression. Psychiatry Res 1987;21:33-41.
24 Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44:1077-8.
25 Marazziti D, Dell’Osso L, Rossi A, Marsala I, Baroni S, Armani A, et al. Decreased platelet H paroxetine binding sites in suicide attempters. Psychiatry Res 2001;103:125-31.
26 Marazziti D, Conti L. Aggression, hyperactivity and platelet imipramine binding. Acta Psychiatrica Scandinavica 1991;84 3:209-11.
27 Marazziti D, Rotondo A, Presta S, Pancioli-Guadagnucci ML, Palego L, Conti L. Role of serotonin in human aggressive behaviour. Aggressive Behav 1993;19:347-53.
28 Neuger J, El Khoury A, Kjellman BF, Wahlund B, Aberg-Wistedt A, Stain-Malmgren R. Platelet serotonin functions in untreated major depression. Psychiatry Res 1999;85:189-98.
29 Power AC, Cowen PJ. Neuroendocrine challenge tests: assessment of 5-HT function in anxiety and depression. Mol Aspects Med 1992;13:205-20.
30 Golden RN, Ekstrom D, Brown TM, Ruegg R, Evans DL, Haggerty JJ Jr, et al. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry 1992;149:1168-75.
31 Meltzer HY, Maes M. Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Psychopharmacology 1994;114:635-43.
32 Park SBG, Williamson DJ, Cowen PJ. 5-HT neuroendocrine function in major depression: prolactin and cortisol responses to fenfluramine. Psychol Med 1996;26:1191-6.
33 Flory JD, Mann JJ, Manuck SB, Muldoon MF. Recovery from major depression is not associated with normalization of serotonergic function. Biol Psychiatry 1998;43:320-6.
34 Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, et al. Serotoninergic studies in patients with affective and personality disorders. Arch Gen Psychiatry 1989;46:587-99.
35 Lichtenberg P, Shapira B, Gillon D, Kindler S, Cooper TB, Newman ME, et al. Hormone responses to fenfluramine and placebo challenge in endogenous depression. Psychiatry Res 1992;43:137-46.
36 Goodall EM, Cowen PJ, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology 1993;112:461-6.
37 Park SBG, Cowen PJ. Effect of pindolol on the prolactin response to D-fenfluramine. Psychopharmacology 1995;18:471-4.
38 Fava M, Rosenmbaum JF. Anger attacks in depression. Depress Anxiety 1998;8(Suppl 15):21-4.
39 Arborelius L, Nomikos GG, Grillner P, Hertel P, Hook BB, Hacksell U, et al. 5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram. Naunyn Schmiedebergs Arch Pharmacol 1995;352:157-65.
40 Gardier AM, Malagie I, Trillat AC, Jacquot C, Artigas F. Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam Clin Pharmacol 1996;10:16-27.
41 Romero L, Bel N, Artigas F, de Montigny C, Blier P. Effect of pindolol on the function of pre- and postsynaptic 5-HT1A receptors: in vivo microdialysis and electrophysiological studies in the ratbrain. Neuropsychopharmacology 1996;15:349-60.
42 Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20:427-51.
43 Verkes RJ, Van der Mast RC, Kerkhof AJ, Fekkes D, Hengeveld MW, Tuyl JP, et al. Platlet serotonin, monoamine oxidase activity, and (3h)paroxetine binding related to impulsive suicide atempts and borderline personality disorder. Biol Psychiatry 1998;43:740-6.
44 McAskill R, Mir S, Taylor D. Pindolol augmentation of antidepressant therapy. Br J Psychiatry 1998;173:203-8.
45 Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004;29:252-6.
46 Attar-Levy D, Martinot JL, Blin J, Dao-Castellana MH, Crouzel C, Mazoyer B, et al. The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biol Psychiatry 1999;45:180-6.
47 Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry 1989;46:23-8.
48 Montgomery SA. Pharmacological treatment of obsessive-compulsive disorder. In: Hollander E, Zohar J, Marazziti D, Olivier B, eds. Current insights in obsessive-compulsive. Chichester: Wiley & Sons 1994, pp. 215-226.
49 Piccinelli M, Pini S, Bellantuono C, Wilkinson C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:53-60.
50 Thoren P, Asberg M, Cronholm B. Clomipramine treatment of obsessive-compulsive disorder: a controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-9.
51 Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980;37:1281-5.
52 Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem 1993;60:2319-22.
53 Rausch JJ, Hutchinson J, Li X. Correlations of drug action between human platelets and human brain 5-HT. Biol Psychiatry 1995;137(Suppl):600.
54 Mann CD, Hrdina PD. Sodium dependence of 3H-paroxetine binding and 5-3H-hydroxytryptamine uptake in rat diencephalon. J Neurochem 1992;59:1856-61.
55 Weizman A, Carmi M, Hermesh H, Shahar A, Apter A, Tyano S, et al. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry 1986;143:335-9.
56 Marazziti D, Hollander E, Lensi P, Ravagli S, Cassano GB. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res 1992;42:41-51.
57 Marazziti D, Rossi A, Gemignani A, Giannaccini G, Pfanner C, Milanfranchi A, et al. Decreased 3H-paroxetine binding in obsessive-compulsive patients. Neuropsychobiology 1996;34:184-7.
58 Ravizza L, Maina G, Bogetto F. Episodic and chronic obsessive-compulsive disorder. Depress Anxiety 1997;6:154-8.
59 Pigott TA, Zohar J, Hill JL, Bernstein SE, Grover GN, Zohar-Kadouch RC, et al. Metergoline blocks the behavioural and neuroendocrine effects of orally administered m-CPP in patients with obsessive-compulsive disorder. Biol Psychiatry 1991;29:418-26.
60 Bastani B, Nash JF, Meltzer HY. Prolactin and cortisol response to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:946-51.
61 Broocks A, Pigott TA, Hill JL, Canter S, Grady TA, L'Heureux F, et al. Acute intravenous administration ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder: bahavioral and biological results. Psychiatry Res 1998;79:11-20.
62 Blier P, De Montigny C. Possible serotonergic mechanism underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol Psychiatry 1998;44:312-23.
63 Anderson GM, Horne WC. Activators of protein kinase C decrease serotonin transport in human platelets. Biochim Biophys Acta 1992;1137:331-7.
64 Marazziti D, Masala I, Rossi A, Hollander E, Presta S, Giannaccini G, et al. Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD. Neuropsychobiology 2000;41:171-7.
65 Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153:1219-21.
66 Hollander E. Obsessive-compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors. Int Clin Psychopharmacol 1996;11(Suppl 5):75-87.
67 Marazziti D, Dell'Osso L, Presta S, Pfanner C, Rossi A, Masala I, et al. Platelet 3H paroxetine binding in patients with OCD-related disorders. Psychiatry Res 1999;89:223-8.
68 Den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 1990r;31:267-78.
69 Kahn RS, Asnis GM, Wetzler S, van Praag HM. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 1988;96:360-4.
70 Kahn RS, Kalus O, Wetzler S, Cahn W, Asnis GM, van Praag HM. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Res 1990;33:189-98.
71 Judd FK, Norman TR, Burrows GD, McIntyre IM. The dexamethasone suppression test in panis disorder. Pharmacopsychiatry 1987;20:99-101.
72 Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 1989;28:295-306.
73 Apostolopoulos M, Judd FK, Burrows GD, Norman TR. Prolactin response to dl-fenfluramine in panic disorder. Psychoneuroendocrinology 1993;18:337-42.
74 Marazziti D, Rossi A, Dell’Osso L, Palego L, Placidi GP, Giannaccini G, et al. Decreased plateled 3H-paroxetine binding in untreated panic disorder patients. Life Sci 1999;65:2735-41.
75 Anderson G, Horne WC. Activators of protein Kinase C decrease serotin transport in human platelets. Biochim Biophys Acta 1992;1137:331-7.
76 Markourakis T, Gorenstein C, Brandao de Almeida Prado E, Ramos RT, Glezer I, Bernardes CS, et al. Panic disorder patients have reduced Cyclic AMP in platelets. J Psychiatr Res 2001.
77 Furmark T, Tillfors M, Garpenstrand H, Marteinsdottir I, Langstrom B, Oreland L, et al. Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett 2004;362:189-92.
78 LeDoux J. Fear and the brain: where have we been, and where are we going? Biol Psychiatry 1998;44:1229-38.
79 Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24- week study. Arch Gen Psychiatry 2002;59:1111-8.
80 Tillfors M, Furmark T, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, et al. Cerebral blood flow in subjects with social phobia during stressful speaking tasks: a PET study. Am J Psychiatry 2001;158:1220-6.
81 Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, et al. Paroxetine in the treatment generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996;16:218-22.
82 Kahn RJ, McNair DM, Lipman RS, Covi L, Rickels K, Downing R, et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious outpatients. Arch Gen Psychiatry 1986;43:79-85.
83 Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder. J Clin Psychiatry 1988;49:293-301.
84 McLeod DR, Hoehn-Saric R, Zimmerli WD, De Souza EB, Oliver LK. Treatment effects of alprazolam and imipramine: physiological versus subjective changes in patients with generalized anxiety disorder. Biol Psychiatry 1990;28:849-61.
85 Den Boer JA, Westenberg HG, Kamerbeek WD, Verhoven WM, Kahn RS. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32.
86 Birmaher B, Waterman GS, Ryan N, Cully M, Balach L, Ingram J, et al. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 1994;33:993-9.
87 Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiat Scand 1997;95:444-50.
88 Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety - A pooled multistudy, double-blind evaluation of buspirone. Neuropsychobiology 1989;21:124-30.
89 Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, et al. Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomised controlled studies. Neuropsychobiology 1992;25:193-201.
90 Haskins T, Rudolph R, Pallay A, Derivan A. Double-blind placebo controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder (GAD). Presented at the Anxiety Disorder Association of America Scientific Satellite Metting. Boston, Massachusetts: March 25-26, 1988.
91 Sheehan DV, Raj BA, Trehan RR, Knapp EL. Serotonin in panic disorder and social phobia. Int Clin Psychopharmacol 1993;8(Suppl 2):63-77.
92 Schneier FR, Jihad BS, Campeas R, Fallon BA, Hollander E, Coplan J, et al. Buspirone in social phobia. J Clin Psychopharmacological 1993;13:251-6.
93 Shlik J, Maron E, Tru I, Aluoja A, Vasar V. Citalopram challenge in social anxiety disorder. Int J Neuropsychopharmacol 2004;7:177-82.
94 Lesch KP, Mayer S, Disselkamp-Tietze J, Weismann M, Osterheider M, Sculte HM. 5HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 1990;28:620-8.
95 Rausch JL, Stahl SM, Hauger R. Cortisol and growth hormone response to the 5-HT1A agonist gepirone in depressed patients. Biol Psychiatry 1990;28:73-8.
96 Blier P, de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1987;1:470-80.
97 den Boer JA. Social phobia: epidemiology, recognition and treatment. Br Med J 1997;315:796-800.
98 Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-8.
99 Pratt J, Lenner P, Reynolds EH, Marsden CD. Clonazepam induced decreased serotoninergic activity in the mouse brain. Neuropharmacology 1979;18:791-9.
100 Schneier FR. Treatment of social phobia with antidepressants. J Clin Psychiatry 2001;62(Suppl 1):43-8.
101 Lydiard RB. The role of drug therapy in social phobia. J Affect Disord 1998;50(Suppl 1S):35-9.
102 Liebowitz MR. Update on the diagnosis and treatment of social anxiety disorder. J Clin Psychiatry 1999;60(Suppl 18):22-6.
103 van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994;115:128-34.
104 Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756-60.
105 Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24- week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003;6:317-23.
106 Van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J Affect Disord 1994;31:141-5.
107 Munjack DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline in social phobia. Anxiety 1994;1:196-8.
108 Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-71.
109 Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. Sertraline treatment of generalized social phobia: a 20 week, double blind, placebo controlled study. Am J Psychiatry 2001;158:275-81.
110 Liebowitz MR, De Martinis N, Weihs K, Lonborg PD, Smith WT, Chung H, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:785-92.
111 Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyard R, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004;161:1642-9.
112 Blomhoff S, Haug TT, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Randomized controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br J Psychiatry 2001;179:23-30.
113 Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 2003;182:312-8.
114 Van Ameringen MA, Oakman J, Mancini C, Pipe B, Chung H. Predictors of response in generalized social phobia: effect of age of onset. J Clin Psychopharmacol 2004;24:42-8.
115 Stein MB, Chartier MJ, Hazen AL, Kroft CD, Chale RA, Cote D, et al. Paroxetine in the treatment of generalized social phobia. Open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996;16:218-22.
116 Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomized, double-blind, placebo-controlled study. Paroxetine study group. Br J Psychiatry 1999;175:120-6.
117 Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002;59:1111-8.
118 Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002;63:152-5.
119 Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998;49:79-82.
120 Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-32.
121 Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychoparmacol 2002;22:257-62.
122 Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31:767-71.
123 Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999;14:239-45.
124 Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19:387-96.
125 Van Ameringen M, Mancini C, Oakman JM. Nefazodone in social phobia. J Clin Psychiatry 1999;60:96-100.
126 Brodie BB, Shore PA. A concept for the role of serotonin and norepinephrine as chemical mediators in the brain. Ann NY Acad Sci 1957;66:631-42.
127 McGuirk L, Muscat R, Willner P. Effects of chronically administred fluoxetine and fenfluramine on food intake, body weight and the behavioural satiety sequence. Psychopharmacology 1992;106:401-7.
128 Leibowitz S, Alexander J. Hypotalamic serotonin in control of eating behaviour, meal size, and body weight. Biol Psychiatry 1998;44:851-64.
129 Leibowitz SF, Weiss GF, Shor-Posner G. Hypotalamic serotonin: Pharmacological, biochemical, and behavioural analyses of its feeding-suppressive action. Clin Neuropharmacol 1988;11(Suppl):S51-S71.
130 Garattini S. Biological actions of drugs affecting serotonin and eating. Obes Res suppl 1995;4:463S-470S.
131 Simansky KJ. 5-HT receptor subtypes influencing feeding and drinking: Focus on the periphery. In: Cooper SJ, Clifton PG, eds. Drug Receptor Subtypes and Ingestive Behaviour Academic Press. London 1996, pp. 59-97.
132 Simansky KJ. Serotonergic control of the organization of feeding and satiety. Behav Brain Res 1996;73:37-42.
133 Curzon G. Serotonin and appetite. Ann NY Acad Sci 1990;600:521-30.
134 Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs dependes on 5HT receptors but not 5HT availability. TIPS 1997;18:21-5.
135 Sakaguchi T, Bray GA. Effect of norepinephrine serotonin and tryptophan on the firing rate of sympatethic nerves. Brain Res 1989;492:271-80.
136 Boschmann M, Frenz U, Murphy CM, Noach R. Changes in energy metabolism and metabolite patterns of obese rats after application of dexfenfluramine. Pharmacol Biochem Behav 1996;53:549-58.
137 Scheurink AJ, Leuvenink H, Steffens AB. Metabolic and hormonal responses to hypothalamic administration of norfenfluramine in rats. Phisiol Behav 1993;53:889-98.
138 Leibowitz SF, Weiss GF, Suh JS. Medial Hypothalamic nuclei mediate serotonin’s inhibitory effect on feeding behaviour. Pharmacol Biochem Behav 1990;37:735-7.
139 Weiss GF, Rogacki N, Fueg A, Buchen D, Suh JS, Wong DT, et al. Effect of hypothalamic and peripheral fluoxetine injection on natural patterns of macronutrient intake in the rat. Psychopharmacology 1991;105:467-76.
140 Hill AJ, Blundell JE. Model system for investigating the actions of anorectic drugs: effects of d-fenfluramine on food intake, nutrients selection, food preferences, meal patterns, hunger and satiety in healthy human subjects. In: Ferrari E, Brambilla F, eds. Advances in the Biosciences. New York: Pergamon Press 1986, pp. 377-389.
141 Kaye WH. Anorexia nervosa, obsessional behavior, and serotonin. Psychopharmacol Bull 1997;33:335-44.
142 Dourish CT, Vickers SP, Clifton PG. Effect of targeted deletion of the 5-HT2C receptor gene on meal patterns and on hypophagia induced by D-fenfluramine. Soc Neurosci Abstr 1997;23:514.
143 Son GH, Baker H, Park DH, Joe TH. Drastic and selective hyperinnervation of central serotonergic neurons in a lethal neurodevelopmental mouse mutant, anorexia (Anx). Brain Res Mol Brain Res 1994;25:129-34.
144 Kaye VH. Persistent alterations in behaviour and serotonin activity after recovery from anorexia and bulimia nervosa. Ann NY Acad Sci 1997;817:162-78.
145 Gorwood P, Bovard M, Moren-Simeoni MC, Kipman A, Feingold J, Ades J. Genetics and anorexia nervosa: a review of candidate genes. Psychiatr Genet 1998;8:1-12.
146 Collier DA, Arranz MJ, Li T, Mupita D, Brown N, Treasure J. Association between 5HT2A gene promoter polymorphism and anorexia nervosa. Lancet 1997;350:412.
147 Campbell DA, Sumdaramurty D, Markham AF, Pieri L. Lack of association between 5HT2A gene promoter polymorphism and susceptibility to anorexia nervosa. Lancet 1998;351:499.
148 Hinney A, Ziegler A, Nothen MA, Remshmidt H, Hebebrand J. 5HT2A receptor gene polymorphism, anorexia nervosa, and obesity. Lancet 1997;350:1324-5.
149 Sorbi S, Nacmias B, Ricca V, Tedde A, Mezzani B, Rotella CM. 5-HT2A promoter polymorphism in anorexia nervosa and bulimia nervosa. Neurosci Let 1999;277:134-6.
150 Sorbi S, Nacmias B, Tedde A, Ricca V, Mezzani A, Rotella CM. 5-HT2A promoter polymorphism in anorexia nervosa. Lancet 1998;351:1575.
151 Gaddum JH. Drug antagonistic to 5 hydroxy-tryptamine. In: Wolstenholme, eds. Ciba Foundation Symposium on hypertension. Boston 1954.
152 Aghajanian GK, Foote WE, Sheard MH. Lysergic acid diethylamide: sensitive neuronal units in the midbrain raphe. Science 1968;161:706-8.
153 Bowers MB Jr. Acute psychosis induced by psychotomimetic drug abuse. II. Neurochemical findings. Arch Gen Psychiatry 1972;27:440-2.
154 Aghajanian GK. Electrophysiology of serotonin receptor subtypes and signal transduction mechanisms. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the Fourth Generation of Progress. New York: Raven Press 1995, pp. 451-460.
155 Bowers MB Jr. Serotonin (5HT) systems in psychotic states. Psychopharmacol Commun 1975;1:655-62.
156 Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984;34:2502-11.
157 Glennon RA. Do classical hallucinogens act as 5-HT2 agonists or antagonists? Neuropsychopharmacology 1990;3:509-17.
158 Martin P, Carlsson ML, Hjorth S. Systemic PCP treatment elevated brain extracellular 5-HT: a microdialysis study. Neuroreport 1999.
159 Lindefors N, Barati S, O’Connor WT. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res 1997;759:205-12.
160 Nordström A-L, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-9.
161 Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 2000;31:302-12.
162 Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emission tomography studies on D-2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 1995;15:S19-S23.
163 Wehren A, De Lisi R, Arnold M. The development of noun definition. J Child Lang 1981;8:165-75.
164 Muck-Seler D, Jakovljevic M, Deanovic Z. Time course of schizophrenia and platelet 5-HT level. Biol Psychiatry 1988;23:243-51.
165 Sedvall GC, Wode-Helgodt B. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients. Arch Gen Psychiatry 1980;37:1113-6.
166 Gattaz WF, Waldmeier P, Beckmann H. CSF monoamine metabolism in schizophrenic patients. Acta Psychiatr Scan 1982;66:350-60.
167 Nyback H, Berggren BM, Hindmarsh T. Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatr Res 1983;9:301-8.
168 Bleich A, Brown SL, Kahn R. The role of serotonin in schizophrenia. Schizophr Bull 1988;14:297-315.
169 Crow TJ, Baker HF, Cross AJ, Joseph MH, Lofthouse R, Longden A, et al. Monomine mechanisms in chronic schizophrenia: Post-mortem neurochemical findings. Br J Psychiatry 1979;134:249-56.
170 Korpi ER, Kleinman JE, Goodman SI. Serotonin and 5-hydroxy-indoleacetic acid in the brains of suicide victims: Comparison in chronic schizophrenic patients with suicide as cause of death. Arch Gen Psychiatry 1986;43:594-600.
171 Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 1986;21:1407-14.
172 Krystal JH, Seibyl JP, Price LH. mChlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993;50:624-35.
173 Wiesel FA, Nordstrom AL, Farde L, Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 1994;114:31-8.
174 Owen RR Jr, Hsiao J, Gutierrez-Esteinou R. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry 1993;50:636-44.
175 Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis Neurology 1996;47:1608-9.
176 Stille G, Lauener H, Eichenberger E. The pharmacology of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)(1,4)diazepine(clozapine). Farmaco 1971;26:603-25.
177 Simpson GM, Varga E. Clozapine – a new antipsychotic agent. Curr Ther Res Clin Exp 1974;16:679-86.
178 Iqbal N, Van Praag HM. The role of serotonin in schizophrenia. In: Den Boer JA, Westenberg HGM, Van Praag HM, eds. Advances in Neurobiology of schizophrenia. London: John Wiley & Sons Ltd 1995.
179 Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989;251:238-46.
180 Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-10.
181 Vogt IR, Shimron-Abarbanell D, Neidt H, Erdmann J, Cichon S, Schulze TG, et al. Investigation of the human serotonin 6 (5-HT6) receptor gene in bipolar affective disorder and schizophrenia. Am J Med Genet 2000;96:217-21.
182 Shinkai T, Ohmori O, Kojima H, Terao T, Suzuki T, Abe K. Association study of the 5-HT6 receptor gene in schizophrenia. Am J Med Genet 1999;88:120-2.
183 Ohmori O, Shinkai T, Hori H, Nakamura J. Novel polymorphism in the 5µ-upstream region of the human 5-HT6 receptor gene and schizophrenia. Neurosci Lett 2001;310:17-20.
184 Breier A Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995;14:187-202.